| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695367 | Gynecologic Oncology | 2017 | 7 Pages |
Abstract
This first report of immunotherapy evaluation in biochemical-only relapse ovarian cancer and of IDO1 inhibitor monotherapy in ovarian cancer found no significant difference in efficacy between epacadostat and tamoxifen. Epacadostat was generally well tolerated.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Rebecca Kristeleit, Irina Davidenko, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko, Michael J. Goodheart, Vera Gorbunova, Carol A. Penning, Jack G. Shi, Xiangdong Liu, Robert C. Newton, Yufan Zhao, Janet Maleski, Lance Leopold, Russell J. Schilder,